Transaction · 0001229055-26-000002

Pierce Frederick II

PIERCE FREDERICK II, CEO, reported a transaction classified as grant at Decoy Therapeutics Inc. involving 33455.000000 shares for an estimated $0.00. Reported holdings after the transaction were 34844.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

grantSEC transaction code ACEO
DCOYDecoy Therapeutics Inc.
Trade date
Aug 31, 2026
Filing date
Sep 02, 2026
View on SEC Insider profile
Estimated value$0Shares × reported price
Shares traded33.4k$0.00 per share
Holdings after34.8kDirect
% of reported position tradedUnavailableThis security and ownership context
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

DCOY price since this filing

Daily closing prices, with the filing date and available return windows
DCOY · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago1w ago1d ago
Returns since7d30d90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
grant
Code A
Identifier
0001229055-26-000002
Common Stock
Transaction date
Aug 31, 2026
Filed Sep 02, 2026, 09:50 PM · 2d delay
Shares
33,455 sh
$0.00 per share
Estimated value
$0
Computed from shares × price
Holdings after
34,844 sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Direct Ownership Large Holdings Increase
Filing-only score

-12 points

Compact filing score computed from stored Form 4 facts. Version v1.

Mixed or weak signal

This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.

How this score is calculated
  • direct_ownership+6 points

    direct_or_indirect_ownership = D

    Direct ownership reports the insider's personal stake.
  • timely_filing+4 points

    reporting_delay_days = 2

    Filing reported within two business days of the transaction.
  • grant_or_award-22 points

    transaction_code = A

    Grant or award transactions are scheduled compensation, not discretionary.
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

Chief Executive Officer

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    Restricted stock granted under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan. 25 percent of the restricted stock vested immediately, and the remainder will vest in approximately equal monthly…

  2. F2

    Shares beneficially owned following the transaction have been adjusted to reflect the reverse stock split effective on March 6, 2026.

Original filing · 0001229055-26-000002
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

DCOY